Duchenne News Tags: PTC Therapeutics

May 20, 2024
On May 20, 2024, PTC Therapeutics announced that the European Commission (EC) has decided not to adopt the CHMP’s negative opinion of January 24, 2024 on the annual renewal of...
March 19, 2024
PTC plans to re-submit an NDA for Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy.
December 15, 2023
A letter to the Duchenne community from PTC Therapeutics about current regulatory processes for Translarna.
PTC Duchenne News
November 22, 2022
PTC Therapeutics, Inc. shares a community letter to the Duchenne community
PTC Duchenne News
June 20, 2022
On June 20, 2022, PTC Therapeutics, Inc. announced they will be hosting a call to review topline results from Study 041 for Translarna.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open